从实验室到临床:儿童胶质瘤溶瘤病毒治疗现状
儿童胶质瘤是儿童最常见的肿瘤类型,高级别胶质瘤在手术切除后常需放疗联合辅助化疗,但现有化疗药物系统毒性大且成人与儿童胶质瘤分子生物学差异显著。本文综述多种溶瘤病毒的分子机制及其在肿瘤细胞系和小鼠模型中的疗效,并总结正在进行的儿童胶质瘤溶瘤病毒治疗I期临床试验。
要点
- 儿童与成人胶质瘤分子生物学差异显著,现有化疗在儿童中的应用存疑。
- 溶瘤病毒基于儿童肿瘤细胞生物学设计,具有高肿瘤特异性并保护健康组织。
- 临床前研究结果积极,相关I期临床试验正在评估儿童胶质瘤治疗。
核心结论
- 溶瘤病毒治疗基于儿童肿瘤细胞生物学,具有高肿瘤特异性且可保护健康组织,临床前研究结果积极,I期临床试验正在儿童胶质瘤中开展。
研究设计与样本
- 综述:回顾多种溶瘤病毒的分子机制及其在肿瘤细胞系和小鼠模型中的疗效,并总结正在进行的儿童胶质瘤溶瘤病毒治疗I期临床试验。
主要发现
- 低级别胶质瘤通常适合手术切除,高级别胶质瘤常需放疗联合辅助化疗。
- 分子分型促进了多种药物和免疫制剂的开发,但这些手段系统毒性大。
- 成人与儿童胶质瘤分子生物学差异显著,使现有化疗在儿童和青少年中的应用存疑。
临床怎么用
- 对儿童高级别胶质瘤,现有放化疗方案受限,可关注以儿童肿瘤细胞生物学为基础、高肿瘤特异性的溶瘤病毒治疗。
- 临床决策时可参考正在开展的儿童胶质瘤溶瘤病毒I期临床试验。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Glioma continues to be a challenging disease process, making up the most common tumor type within the pediatric population. While low-grade gliomas are typically amenable to surgical resection, higher grade gliomas often require additional radiotherapy in conjunction with adjuvant chemotherapy. Molecular profiling of these lesions has led to the development of various pharmacologic and immunologic agents, although these modalities are not without great systemic toxicity. In addition, the molecular biology of adult glioma and pediatric glioma has been shown to differ substantially, making the application of current chemotherapies dubious in children and adolescents. For this reason, therapies with high tumor specificity based on pediatric tumor cell biology that spare healthy tissue are needed. Oncolytic virotherapy serves to fill this niche, as evidenced by renewed interest in this domain of cancer therapy. Initially discovered by chance in the early 20th century, virotherapy has emerged as a viable treatment option. With promising results based on preclinical studies, the authors review several oncolytic viruses, with a focus on molecular mechanism and efficacy of these viruses in tumor cell lines and murine models. In addition, current phase I clinical trials evaluating oncolytic virotherapy in the treatment of pediatric glioma are summarized.
引用
- Soldozy S, Skaff A, Soldozy K, et al. From Bench to Bedside, the Current State of Oncolytic Virotherapy in Pediatric Glioma. Neurosurgery. 2020. PMID: 32542365. doi:10.1093/neuros/nyaa247
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。